Company Analysis
Sign in

Prime Medicine, Inc. (PRME)

Nasdaq: PRME · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.1
◀ Past 3.7● Present 3.0▶ Future 5.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Prime Medicine, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.1/10
◀ Past3.725% of the headline
● Present3.035% of the headline
▶ Future5.440% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.7/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.0/10

Has it survived what it has been through?

No warning events in its filings since 2021.

weight 22% of this tense · 80th percentile among 159 sector filers · read for itself

From the record

Prime Medicine, Inc.'s filings since 2021 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
2.6/10

What has it actually done, year after year?

-2.3% a year over 6 filed years; profitable in 0 of 6.

weight 45% of this tense · 26th percentile among 102 sector filers · read for its customers

From the record

Prime Medicine, Inc.'s 6 filed years say what it did: revenue went from $5 million in fiscal 2020 to $5 million in fiscal 2025, down 2.3% a year; it rose in 1 of 2 years; the deepest fall was 100% from fiscal 2020 to fiscal 2021; net income was positive in 0 of 6 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-2.3%bottom 22% of its family
  • the share of years revenue rosebottom 42% of its family
  • the share of filed years with a profitbottom 31% of its family
  • the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
2.2/10

How has it treated the people who own it?

SI estimate 2.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 22nd percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 22% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Prime Medicine, Inc.'s shareholder treatment is put at 2.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 22% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.0/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
2.8/10

Is it financially healthy right now?

ROE -166%: lost 166¢ per shareholder dollar. Leverage 65%: owes 65¢ per asset dollar.

weight 45% of this tense · 28th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Prime Medicine, Inc. lost about 166 cents for every dollar of shareholders' money. Leverage: it owed about 65 cents per dollar of assets, and net share issuance: its share count grew 25.4% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 31% of its family
  • return on equitybottom 16% of its family
  • the share count against the year beforebottom 37% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
2.5/10

How strong is its position in its industry?

bottom 26% of 102 in its family; net margin -4342.4%.

weight 22% of this tense · 26th percentile among 102 sector filers · read for its customers

From the record

Prime Medicine, Inc.'s standing among 102 graded names in its industry family: revenue of $5 million in fiscal 2025 ranks in the bottom 31% by size; a net margin of -4342.4% ranks in the bottom 21% (its annual reports).

What it rests on

  • revenue against the family$4.6Mbottom 31% of its family
  • net margin-4342.4%bottom 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
3.5/10

What are the people in charge doing?

bottom 35% of 110 in its family for leadership; chief executive since 2025.

weight 33% of this tense · 35th percentile among 110 sector filers · read for its shareholders

From the record

Prime Medicine, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Reine, Allan (Chief Executive Officer, as filed), filing under that title since 2025-05-19, 1.5 years (bottom 18% of its family); most of the 11 officers and directors filing now have filed since the record of its people begins (2022-10-19), a floor of 4.1 years the record cannot see past, so that part is not read; 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge5 in three years among 11 peopletop 47% of its family
  • the chief executive's years on the record1.5 yearsbottom 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
5.0/10

How much room does it have to grow?

bottom 50% of 92 in its family for room to expand.

weight 33% of this tense · 50th percentile among 92 sector filers · read for itself

From the record

Prime Medicine, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $77 million against no long-term debt tagged leaves 22.4% of its assets as net cash, bottom 44% of its family; cash from operations less capital spending is -3607.4% of revenue (bottom 18%); research spending of 3468% of revenue (top 14%) (its annual report).

What it rests on

  • cash less debt against assets22.4%bottom 44% of its family
  • cash from operations less capital spending against revenue-3607.4%bottom 18% of its family
  • research spending against revenue3468.0%top 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
6.7/10

What could actually drive growth from here?

top 33% of 100 in its family for growth drivers.

weight 45% of this tense · 67th percentile among 100 sector filers · read for its customers

From the record

Prime Medicine, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 55.3% (top 32%); research spending grew 22.8% a year (top 16%); capital spending grew -34.5% a year (bottom 48%) (its annual reports). Prime Medicine, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • the newest year's revenue growth55.3%top 32% of its family
  • three-year growth of research spending22.8%top 16% of its family
  • three-year growth of capital spending-34.5%bottom 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
3.3/10

Did its newest year beat what its own record pointed to?

SI estimate 3.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 33rd percentile among 90 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, net income against the prior three years' average, which ranks in the bottom 33% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: net income against the prior three years' average, the one part on file, ranked among 90 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Prime Medicine, Inc.'s expectations vs reality is put at 3.3 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 33% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PRME · research, not advice